Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease

Clinical Chemistry

Volumn 52, Issue 1, 2006, Pages 53-58

  Kerkeni, Mohsen ^a,b,c   Addad, Faouzi ^b   Chauffert, Maryline ^c   Myara, Anne ^c   Farhat, Mohamed Ben ^b   Miled, Abdelhedi ^d   Maaroufi, Khira ^a   Trivin, François ^c,d,e  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c SAINT JOSEPH HOSPITAL   (France)

^d FARHAT HACHED HOSPITAL   (Tunisia)

^e UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENE PRODUCT; GUANINE; HOMOCYSTEINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA EXTRACTION; ENOS GENE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUNISIA;

CONSTRICTION, PATHOLOGIC; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRIC OXIDE SYNTHASE TYPE III; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TUNISIA;

EID: 29744447478     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.057950     Document Type: Article

References (41)

1. Gotto AM. Interactions of the major risk factors for coronary heart disease. Am J Med 1986;80:48-55.
2. Kannel WB: Clinical misconceptions dispelled by epidemiological research. Circulation 1995;92:3350-60.
3. Wilson PW, D'Agastino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, et al. Prediction of coronary heart disease using risk factors categories. Circulation 1998;97:1837-47.
4. Marenberg ME, Risch N, Berkmari LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.
5. Boerwinkle E, Ellsworth DL, Hallman DM, Biddinger A. Genetic analysis of atherosclerosis: a research paradigm for the common diseases. Hum Mol Genet 1996;5:1405-10.
6. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium [Review]. N Engl J Med 1990;323:27-36.
7. Moncada S, Higgs A. The L-arginine-nitric oxide pathway [Review]. N Engl Med 1993;329:2002-12.
8. Schmidt HH, Walter U. NO at work. Cell 1994;78:919-25.
9. Danishpajooh IO, Gudi T, Chen Y, Kharitonov VG, Sharma VS, Boss GR. Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway. J Biol Chem 2001;276:27296-303.
10. Juckett MB, Weber M, Balla J, Jacob HS, Vercellotti GM. Nitric oxide donors modulate ferritin and protect endothelium from oxidative injury. Free Radic Biol Med 1996;20:63-73.
11. Suh JR, Oppenheim EW, Girgris S, Stover PJ. Purification and properties of folate-catabolizing enzyme. J Biol Chem 2000;275:35646-55.
12. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease [Review]. Lab Invest 2001;81:645-72.
13. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
14. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
15. Cayatte AJ, Polacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:753-9.
16. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudgo GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
17. Yashimura M, Yassue H, Nakayama M, Shimaski Y, Sumida H, Sugiyama S, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-9.
18. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk for coronary artery disease in the UK. Circulation 1999;100:1515-20.
19. Vallet-Colom I, Levy-Marchal C, Zarrouk D, Tichet J, Krishnamoorty R, Czermichow P, et al. HLA-DQ B1 codon 57 and genetic susceptibility to type I (insulin-dependent) diabetes mellitus in French children. Diabetologia 1990;33:174-6.
20. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998;137:23-8.
21. Gardemann A, Weidemann H, Philipp M, Katz N, Tillmanns H, Wilhelm Hehrlein F, et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 1999;20:584-92.
22. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A; Musicco M, et al. A common variant of the endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001;32:735-40.
23. Szolnoki Z, Havasi V, Bene J, Komlosi K, Szoke D, Somogyvari F, et al. Endothelial nitric oxide synthase gene interactions and the risk of ischaemic stroke. Acta Neurol Scand 2005;111:29-33.
24. Shimasaki Y, Yasue H, Yashimura M, Nakayama M, Kugiyama K, Ogawa H, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998;31:1506-10.
25. Heil SG, Den Hajer M, Van der rijt-pisa BJM, Kluijtmans LA, Blom HJ. The G894T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels. J Thromb Haemost 2004;2:750-3.
26. Hibi K, Lshigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension. 1998;32:521-6.
27. Casas JP, Bautista LE, Humphries SE, Hingorani AD, Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004;109:1359-65.
28. Cai H, Wilken DE, Wang XL. The Glu298Asp (G894T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med 1999;77:511-4.
29. Granath B, Taylor RR, Van Bockxmeer FM, Mamotte CD. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 2001;8:235-41.
30. Wang CL, Hsu LA, Ko YS, Ko YL, Lee YH. Lack of association between the Glu298Asp variant of the endothelial nitric oxide synthase gene and the risk of coronary artery disease among Taiwanese. J Formos Med Assoc 2001;100:736-40.
31. Schmoelzer I, Renner W, Paulweber B, Malaimare L, Iglseder B, Schmid P, et al. Lack of association between the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest 2003;33:191-8.
32. Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Masetti S, et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 2002;87:525-8.
33. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003;49:389-95.
34. Agema WRP, Maat MPM, Zwinderman AH, Kastelein JJP, Rabelink TJ, Boven AJ, et al. An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin Sci 2004;107:255-61.
35. Yoon S, Shin C, Park HY, Moon J, Kim E, Kim HT, et al. Endothelial nitric oxide synthase gene is associated with vessel stenosis in Korean population. Clin Chim Acta 2005;353:177-85.
36. Brown KS, Kluijtmans LAJ, Young IS, Woodside J, Yarnell JWG, McMaster D, et al. Genetic evidence that nitric oxide modulates homocysteine, the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2003;23:1014-20.
37. Fisher PA, Dominguez GN, Cuniberti LA, Martinez V, Werba JP, Ramirez AJ, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved? [Review]. J Am Soc Nephrol 2003;14:653-60.
38. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41:1444-54.
39. Dayal S, Arming E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemia mice. Stroke 2004;35:1957-62.
40. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
41. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000;97:2832-5.